• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Bridge Biotherapeutics

Monday, June 03, 2024
CP
Multiple Therapeutics
Bridge Biotherapeutics Inc., based in the Republic of Korea and the U.S., is a publicly traded, clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high unmet needs, including fibrotic diseases and cancers. The company is developing BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF), and BBT-207, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with EGFR C797S mutations.
Bridge Biotherapeutics
Company Website: https://bridgebiorx.com/en/
Lead Product in Development: BBT-877

Exchange

KOSDAQ

Ticker

288330

Company HQ City

Pangyo

Company HQ State

Gyeongi-do

Company HQ Country

Korea, Republic of

CEO/Top Company Official

James Lee

Development Phase of Primary Product

Phase II
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS